Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Decreased TSPAN1 promotes prostate cancer progression and is a marker for early biochemical recurrence after radical prostatectomy.

Xu F, Gao Y, Wang Y, Pan J, Sha J, Shao X, Kang X, Qin J, You MJ, Huang Y, Dong B, Xue W.

Oncotarget. 2016 Sep 27;7(39):63294-63305. doi: 10.18632/oncotarget.11448.

2.

Prioritization of anticancer drugs against a cancer using genomic features of cancer cells: A step towards personalized medicine.

Gupta S, Chaudhary K, Kumar R, Gautam A, Nanda JS, Dhanda SK, Brahmachari SK, Raghava GP.

Sci Rep. 2016 Mar 31;6:23857. doi: 10.1038/srep23857.

3.

MicroRNA-425-5p regulates chemoresistance in colorectal cancer cells via regulation of Programmed Cell Death 10.

Zhang Y, Hu X, Miao X, Zhu K, Cui S, Meng Q, Sun J, Wang T.

J Cell Mol Med. 2016 Feb;20(2):360-9. doi: 10.1111/jcmm.12742. Epub 2015 Dec 9.

4.

Downregulation of programmed cell death 10 is associated with tumor cell proliferation, hyperangiogenesis and peritumoral edema in human glioblastoma.

Lambertz N, El Hindy N, Kreitschmann-Andermahr I, Stein KP, Dammann P, Oezkan N, Mueller O, Sure U, Zhu Y.

BMC Cancer. 2015 Oct 21;15:759. doi: 10.1186/s12885-015-1709-8.

5.

Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer.

Wang C, Xie J, Guo J, Manning HC, Gore JC, Guo N.

Oncol Rep. 2012 Oct;28(4):1301-8. doi: 10.3892/or.2012.1951. Epub 2012 Aug 6.

6.

Changes in leukocyte gene expression profiles induced by antineoplastic chemotherapy.

González-Fernández R, Morales M, Avila J, Martín-Vasallo P.

Oncol Lett. 2012 Jun;3(6):1341-1349. Epub 2012 Apr 3.

7.

Tetraspanin CO-029 inhibits colorectal cancer cell movement by deregulating cell-matrix and cell-cell adhesions.

Guo Q, Xia B, Zhang F, Richardson MM, Li M, Zhang JS, Chen F, Zhang XA.

PLoS One. 2012;7(6):e38464. doi: 10.1371/journal.pone.0038464. Epub 2012 Jun 5.

8.

Subtype and pathway specific responses to anticancer compounds in breast cancer.

Heiser LM, Sadanandam A, Kuo WL, Benz SC, Goldstein TC, Ng S, Gibb WJ, Wang NJ, Ziyad S, Tong F, Bayani N, Hu Z, Billig JI, Dueregger A, Lewis S, Jakkula L, Korkola JE, Durinck S, Pepin F, Guan Y, Purdom E, Neuvial P, Bengtsson H, Wood KW, Smith PG, Vassilev LT, Hennessy BT, Greshock J, Bachman KE, Hardwicke MA, Park JW, Marton LJ, Wolf DM, Collisson EA, Neve RM, Mills GB, Speed TP, Feiler HS, Wooster RF, Haussler D, Stuart JM, Gray JW, Spellman PT.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2724-9. doi: 10.1073/pnas.1018854108. Epub 2011 Oct 14.

9.

Predictive and prognostic molecular markers for cancer medicine.

Mehta S, Shelling A, Muthukaruppan A, Lasham A, Blenkiron C, Laking G, Print C.

Ther Adv Med Oncol. 2010 Mar;2(2):125-48. doi: 10.1177/1758834009360519.

11.

PDCD10 interacts with Ste20-related kinase MST4 to promote cell growth and transformation via modulation of the ERK pathway.

Ma X, Zhao H, Shan J, Long F, Chen Y, Chen Y, Zhang Y, Han X, Ma D.

Mol Biol Cell. 2007 Jun;18(6):1965-78. Epub 2007 Mar 14.

12.

Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line.

Zhang P, Zhang Z, Zhou X, Qiu W, Chen F, Chen W.

BMC Cancer. 2006 Sep 15;6:224.

13.

Tetraspanins in viral infections: a fundamental role in viral biology?

Martin F, Roth DM, Jans DA, Pouton CW, Partridge LJ, Monk PN, Moseley GW.

J Virol. 2005 Sep;79(17):10839-51. Review. No abstract available.

14.

The tetraspanin D6.1A and its molecular partners on rat carcinoma cells.

Claas C, Wahl J, Orlicky DJ, Karaduman H, Schnölzer M, Kempf T, Zöller M.

Biochem J. 2005 Jul 1;389(Pt 1):99-110.

15.

CF101, an agonist to the A3 adenosine receptor, enhances the chemotherapeutic effect of 5-fluorouracil in a colon carcinoma murine model.

Bar-Yehuda S, Madi L, Silberman D, Gery S, Shkapenuk M, Fishman P.

Neoplasia. 2005 Jan;7(1):85-90.

Supplemental Content

Support Center